Advertisement

Pharmaceutisch Weekblad

, Volume 6, Issue 6, pp 229–236 | Cite as

Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review

  • R. Janknegt
  • C. H. W. Koks
Review Articles

Abstract

Since its introduction some years ago continuous ambulatory peritoneal dialysis (CAPD) has proved to be a valuable alternative to haemodialysis in the treatment of uraemia. Factors contributing to the transport of solutes through the peritoneal membrane are discussed and the literature concerning the pharmacokinetic aspects of CAPD is reviewed.

Keywords

Public Health Internal Medicine Peritoneal Dialysis Continuous Ambulatory Peritoneal Dialysis Valuable Alternative 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Popovich RP, Moncrief JW, Nolph KD, Ghods AJ, Twardowski ZJ, Pyle WK. Continuous ambulatory peritoneal dialysis. Ann Intern Med 1978;88:449–56.PubMedGoogle Scholar
  2. 2.
    Rubin J, Rogers WA, Taylor HM, et al. Peritonitis during continuous peritoneal dialysis. Ann Intern Med 1980;92:7–13.PubMedGoogle Scholar
  3. 3.
    Wu G. A review of peritonitis episodes that caused interruption of CAPD. Perit Dial Bull 1983;3:S11–S3.Google Scholar
  4. 4.
    Fenton SS. Peritonitis-related deaths among CAPD-patients. Perit Dial Bull 1983;3:S9–S11.Google Scholar
  5. 5.
    Fenton SS, Wu G, Cattran D, et al. Clinical aspects of peritonitis in patients of CAPD. Perit Dial Bull 1981;1:S54–S7.Google Scholar
  6. 6.
    Manuel MA, Paton TW, Cornish WR. Drugs and peritoneal dialysis. Perit Dial Bull 1983:3:117–25.Google Scholar
  7. 7.
    Maher JF. Transport kinetics in peritoneal dialysis. Perit Dial Bull 1982;2:S4–S6.Google Scholar
  8. 8.
    Maher JF. Transport kinetics of drugs and peritoneal dialysis. In: Gahl GM, Kessel M, Nolph KD, eds. Advances in peritoneal dialysis. Proceedings of the Second International Symposium on Peritoneal Dialysis. Amsterdam: Excerpta Medica, 1981:37–40.Google Scholar
  9. 9.
    Maher JF, Hirszel P, Lasrich M. An experimental model for study of pharmacologic and hormonal influences on peritoneal mass transport. Contrib Nephrol 1979;17:131–8.PubMedGoogle Scholar
  10. 10.
    Maher JF, Hirszel P, Lasrich M. Prostaglandin effects on peritoneal transport. In: Gahl GM, Kessel M, Nolph KD, eds. Advances in peritoneal dialysis. Proceedings of the Second International Symposium on Peritoneal Dialysis. Amsterdam: Excerpta Medica, 1981:65–72.Google Scholar
  11. 11.
    Maher JF, Hirszel P, Abraham JE, Galen MA, Chamberlin M, Hohnadel DC. Effect of dipyridamole on peritoneal mass transport. Trans Am Soc Artic Intern Organs 1977;23:219–23.Google Scholar
  12. 12.
    Nolph KD, Twardowski ZJ, Popovich RP, Rubin J. Equilibration of peritoneal dialysis solutions during long-dwell exchanges. J Lab Clin Med 1979;93:246–56.PubMedGoogle Scholar
  13. 13.
    Twardowski ZJ, Ksiazek A, Majdan M, et al. Kinetics of CAPD with four exchanges per day. Clin Nephrol 1981;15:115–30.PubMedGoogle Scholar
  14. 14.
    Randerson DH, Farell PC. Mass transfer properties of the human peritoneum. Am Soc Artific Intern Org J 1980;3:140–6.Google Scholar
  15. 15.
    Paton TW, Manuel MA, Walker SE. Tobramycin disposition in patients on continuous ambulatory peritoneal dialysis. Perit Dial Bull 1982:2:179–81.Google Scholar
  16. 16.
    Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Pharmacokinetics of tobramycin in continuous ambulatory peritoneal dialysis. Clin Res 1982;30:717A.Google Scholar
  17. 17.
    Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Tobramycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;34:110–6.PubMedGoogle Scholar
  18. 18.
    Blouin RA, Bauer LA, Piecoro JJ, Holland NH. Decreased gentamicin half-life during peritoneal dialysis. Drug Intell Clin Pharm 1980;14:218–9.Google Scholar
  19. 19.
    Somani P, Shapiro RS, Stockard H, Higgins JT. Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1982;32:113–21.PubMedGoogle Scholar
  20. 20.
    Paton TW, Manuel MA, Cohen LB, Walker SE. The disposition of cefazolin and tobramycin following intraperitoneal administration in patients on continuous ambulatory peritoneal dialysis. Perit Dial Bull 1983;3:73–6.Google Scholar
  21. 21.
    Königshausen T, Nachtigall W, Pützhofen G, Rosin H. Pharmacokinetics of lamoxactam in patients using continuous ambulatory peritoneal dialysis. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th international congress of chemotherapy. Part 80. Vienna: Egermann, 1983:7–10.Google Scholar
  22. 22.
    Thomae U, Boos W, Adam D. Transperitoneale Resorption von Ampicillin, Cefuroxim und Gentamicin unter kontinuierlicher ambulanter Peritonealdialyse. Med Welt 1982;33:182–4.PubMedGoogle Scholar
  23. 23.
    Thomae U, Boos W, Adam D. Transperitoneale Resorption von Oxacillin, Azlocillin und Sisomicin unter kontinuierlicher ambulanter Peritonealdialyse bei Patienten mit und ohne Peritonitis. Med Welt 1981;32:1365–7.PubMedGoogle Scholar
  24. 24.
    Pancorbo S, Comty C. Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis. Nephron 1982;31:37–9.PubMedGoogle Scholar
  25. 25.
    Bunke C, Aronoff G, Brier M, Sloan R, Luft F. Pharmacokinetics of vancomycin in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;33:263.Google Scholar
  26. 26.
    Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;34:631–7.PubMedGoogle Scholar
  27. 27.
    Matzke GR, Halstenson CE, Blevins RB, Salem NG. Pharmacokinetics of vancomycin during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;33:236.Google Scholar
  28. 28.
    Talbert RL, Brochway BA, Ludden TM. Vancomycin clearance during chronic ambulatory peritoneal dialysis. Drug Intell Clin Pharm 1983;17:442–3.Google Scholar
  29. 29.
    Brumfitt W, Hamilton-Miller J, Gooding A. Pharmacokinetics of rifampin and trimethoprim during peritoneal dialysis. In: Periti P, Grassi GG, eds. Proceedings of the 12th international congress of chemotherapy Vienna: Egermann, 953–4.Google Scholar
  30. 30.
    Matzke GR, Halstenson CE, Blevins RB, Salem NG. Trimethoprim-Sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;33:235.Google Scholar
  31. 31.
    Glasson P, Favre H. Treatment of peritonitis in continuous ambulatory peritoneal dialysis patients with co-trimoxazole. Nephron 1984;36:65–7.PubMedGoogle Scholar
  32. 32.
    Kerr CM, Perfect JR, Craven PC, et al. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med 1983;99:334–7.PubMedGoogle Scholar
  33. 33.
    Chapman JR, Warnock DW. Ketoconazole and fungal CAPD peritonitis. Lancet 1983;2:510–1.CrossRefGoogle Scholar
  34. 34.
    Muther RS, Bennet WM. Peritoneal clearance of amphotericin B and 5-fluorocytosine. West J Med 1980;133:157–60.PubMedGoogle Scholar
  35. 35.
    Lempert KD, Jones JM. Flucytosine-miconazole treatment of Candida peritonitis. Arch Intern Med 1982;142:577–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Khanna R, Oreopoules DG, Vas S, McCready W, Dombros N. Fungal peritonitis in patients undergoing chronic intermittent or continuous ambulatory peritoneal dialysis. Proc EDTA, 1980;17:291–6.Google Scholar
  37. 37.
    Paton TW, Manuel MA, Walker SE. Cimetidine disposition in patients on continuous ambulatory peritoneal dialysis. Perit Dial Bull 1982;2:73–6.Google Scholar
  38. 38.
    Hyneck ML, Murphy JF, Lipschutz DE. Cimetidine clearance during intermittent and chronic peritoneal dialysis. Am J Hosp Pharm 1981;38:1760–2.PubMedGoogle Scholar
  39. 39.
    Kogan FJ, Sampliner RE, Mayersohn M, et al. Cimetidine disposition in patients undergoing continuous ambulatory peritoneal dialysis. J Clin Pharmacol 1983;23:252–6.PubMedGoogle Scholar
  40. 40.
    Pizella KM, Moore MC, Schultz RW, Walshe J, Schentag JJ. Removal of cimetidine by peritoneal dialysis, hemodialysis and charcoal hemoperfusion. Ther Drug Monit 1980;2:273–81.PubMedGoogle Scholar
  41. 41.
    Vaziri ND, Ness RL, Barton CH. Peritoneal dialysis clearance of cimetidine. Am J Gastroenterol 1979;71:572–6.PubMedGoogle Scholar
  42. 42.
    Bodemar G, Norlander B, Walan A. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet 1981;6:306–15.PubMedGoogle Scholar
  43. 43.
    Pancorbo S, Comty C. Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1981;19:605–7.PubMedGoogle Scholar
  44. 44.
    Pancorbo S, Comty C. Pharmacokinetics of cefamandole in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Bull 1983;3:135–8.Google Scholar
  45. 45.
    Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;33:66–72.PubMedGoogle Scholar
  46. 46.
    Matoušovic K, Morávek J, Vitko S, et al. Pharmacokinetics of intravenous and intraperitoneal cefotaxim in patients undergoing CAPD. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th international congress of chemotherapy. Part 80. Vienna: Egermann, 1983:11–4.Google Scholar
  47. 47.
    Greaves WL, Kreeft JH, Ogilvie RI, Richards GK. Cefoxitin disposition during peritoneal dialysis. Antimicrob Agents Chemother 1981;19:253–5.PubMedGoogle Scholar
  48. 48.
    Comstock TJ, Straughn AB, Kraus AP, Meyer MC, Finn AL, Chubb JM. Ceftazidime pharmacokinetics during continuous ambulatory peritoneal dialysis and intermittent peritoneal dialysis. Drug Intell Clin Pharm 1983;17:453.Google Scholar
  49. 49.
    Somani P, Gross ML, Freimer EH, Nally JV, Higgins JT. Ceftizoxime exchange through the peritoneal membrane in renal patients. Clin Pharmacol Ther1983;33:265.Google Scholar
  50. 50.
    Blair AD, Burgess ED. Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;33:249.Google Scholar
  51. 51.
    Burgess ED, Blair AD. Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1983;24:237–9.PubMedGoogle Scholar
  52. 52.
    Gross ML, Freimer EH, Somani P. Pharmacokinetics and peritoneal clearance of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. Clin Res 1982;30:753A.Google Scholar
  53. 53.
    Gross ML, Somani P, Ribner BS, Raeder RH, Freimer EH. Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th international congress of chemotherapy. Part 80. Vienna: Egermann, 1983:3–5.Google Scholar
  54. 54.
    Gross ML, Somani P, Ribner BS, et al. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;34:673–80.PubMedGoogle Scholar
  55. 55.
    Singlas E, Boutron HF, Merdjan H, Brocard JF, Pocheville M, Fries D. Moxalactam kinetics during chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;34:403–7.PubMedGoogle Scholar
  56. 56.
    Paton TW, Manuel MA, Walker SE. Cimetidine disposition in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1981;29:271.Google Scholar
  57. 57.
    De Paoli Vitali E, Casol D, Tessarin C, Tisoni GF, Cavagna R. Pharmacokinetics of digoxin in CAPD. In: Gahl GM, Kessel M, Nolph KD, eds. Advances in peritoneal dialysis. Proceedings of the Second International Symposium on Peritoneal Dialysis. Amsterdam: Excerpta Medica, 1981:85–7.Google Scholar
  58. 58.
    Lameire N, Belpaire F, Bogaert M, et al. A review and studies on digoxin and gentamicin in peritoneal dialysis. In: Atkins RC, Thompson NM, Farrell PC, eds. Edinburgh: Churchill Livingstone, 1981:30–40.Google Scholar
  59. 59.
    DePaepe M, Belpaire F, Bogaerts Y. Pharmacokinetics of digoxin in CAPD. Clin Exp Dial Apheresis 1982;6:65–73.PubMedGoogle Scholar
  60. 60.
    Pancorbo S, Comty C. Digoxin pharmacokinetics in continuous peritoneal dialysis. Ann Intern Med 1980;93:639.Google Scholar
  61. 61.
    Risler T, Peters U, Passlick J, Grabensee B, Krokou J. Pharmacokinetics of digoxin and digitoxin in patients on continuous ambulatory peritoneal dialysis. In: Gahl GM, Kessel M, Nolph KD, eds. Advances in peritoneal dialysis. Proceedings of the Second International Symposium on Peritoneal Dialysis. Amsterdam: Excerpta Medica, 1981:88–9.Google Scholar
  62. 62.
    Chin TW, Pancorbo S, Comty C. Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis. Clin Exp Dial Apheresis 1981;5:391–7.PubMedGoogle Scholar
  63. 63.
    Boutron HF, Brocard JF, Singlas E, Charpentier B, Fries D. Pharmacokinetics of furosemide in CAPD. In: Gahl GM, Kessel M, Nolph KD, eds. Advances in peritoneal dialysis. Proceedings of the Second International Symposium on Peritoneal Dialysis. Amsterdam: Excerpta Medica, 1981:90–2.Google Scholar
  64. 64.
    Hess B, Keusch G, Flückiger J, Binschwanger U. Zur Pharmacokinetik von Phenytoin bei kontinuierlicher ambulanter Peritonealdialyse. Schweiz Med Wochenschr 1984;114:16–9.PubMedGoogle Scholar
  65. 65.
    DePaepe M, Lameire N, Ringoir S, Belpaire F, Bogaert M. Peritoneal pharmacokinetics of gentamicin in man and rabbit. In: Gahl GM, Kessel M, Nolph KD, eds. Advances in peritoneal dialysis. Proceedings of the Second International Symposium on Peritoneal Dialysis. Amsterdam: Excerpta Medica, 1981:99–101.Google Scholar
  66. 66.
    DePaepe M, Lameire N, Belpaire F, Bogaert M. Peritoneal pharmacokinetics of gentamicin in man. Clin Nephrol 1983;19:107–9.PubMedGoogle Scholar
  67. 67.
    Dahlager JI, Ekelund B. Netilmicin in treatment of peritonitis in patients on continuous ambulatory dialysis. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th international congress of chemotherapy. Part 80. Vienna: Egermann, 1983:24–7.Google Scholar
  68. 68.
    Lewis DA, Chapman ST, Kingswood JC, White LO, Banks RA, Reeves DS. Pharmacokinetics of cefotaxime in continuous ambulatory peritoneal dialysis. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th international congress of chemotherapy. Part 80. Vienna: Egermann, 1983:15–8.Google Scholar
  69. 69.
    Petersen J, Stewart RD, Catto GR, Edward N, Ratcliffe P. Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in CAPD patients. In: Spitzky KH, Karrer K, eds. Proceedings of the 13th international congress of chemotherapy. Part 80. Vienna: Egermann, 1983:19–23.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1984

Authors and Affiliations

  • R. Janknegt
    • 1
  • C. H. W. Koks
    • 1
  1. 1.Department of Clinical PharmacyMedical Centre AlkmaarHA AlkmaarThe Netherlands

Personalised recommendations